Arrow Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $217K | Hold |
1,696
| – | – | 0.02% | 154 |
|
|
2025
Q4 | $207K | Buy |
+1,696
| New | +$194K | 0.02% | 156 |
|
|
2024
Q4 | – | Sell |
-1,567
| Closed | -$155K | – | 326 |
|
|
2024
Q3 | $155K | Hold |
1,567
| – | – | 0.01% | 181 |
|
|
2024
Q2 | $145K | Hold |
1,567
| – | – | 0.01% | 175 |
|
|
2024
Q1 | $149K | Hold |
1,567
| – | – | 0.01% | 171 |
|
|
2023
Q4 | $140K | Sell |
1,567
-13
| -0.8% | -$965 | 0.01% | 174 |
|
|
2023
Q3 | $115K | Hold |
1,580
| – | – | 0.01% | 176 |
|
|
2023
Q2 | $131K | Hold |
1,580
| – | – | 0.02% | 165 |
|
|
2023
Q1 | $120K | Hold |
1,580
| – | – | 0.02% | 169 |
|
|
2022
Q4 | $131K | Hold |
1,580
| – | – | 0.02% | 165 |
|
|
2022
Q3 | $125K | Hold |
1,580
| – | – | 0.02% | 167 |
|
|
2022
Q2 | $117K | Hold |
1,580
| – | – | 0.02% | 172 |
|
|
2022
Q1 | $142K | Hold |
1,580
| – | – | 0.02% | 171 |
|
|
2021
Q4 | $176K | Buy |
1,580
+40
| +3% | +$4.82K | 0.02% | 165 |
|
|
2021
Q3 | $194K | Hold |
1,540
| – | – | 0.03% | 165 |
|
|
2021
Q2 | $209K | Hold |
1,540
| – | – | 0.03% | 163 |
|
|
2021
Q1 | $209K | Hold |
1,540
| – | – | 0.03% | 163 |
|
|
2020
Q4 | $217K | Hold |
1,540
| – | – | 0.04% | 151 |
|
|
2020
Q3 | $171K | Hold |
1,540
| – | – | 0.04% | 153 |
|
|
2020
Q2 | $172K | Sell |
1,540
-360
| -19% | -$35.5K | 0.04% | 156 |
|
|
2020
Q1 | $147K | Sell |
1,900
-60
| -3% | -$5.31K | 0.03% | 162 |
|
|
2019
Q4 | $187K | Hold |
1,960
| – | – | 0.04% | 164 |
|
|
2019
Q3 | $150K | Hold |
1,960
| – | – | 0.03% | 169 |
|
|
2019
Q2 | $172K | Hold |
1,960
| – | – | 0.04% | 173 |
|
|
2019
Q1 | $177K | Buy |
1,960
+485
| +33% | +$41.3K | 0.04% | 176 |
|
|
2018
Q4 | $106K | Hold |
1,475
| – | – | 0.03% | 180 |
|
|
2018
Q3 | $142K | Hold |
1,475
| – | – | 0.03% | 180 |
|
|
2018
Q2 | $141K | Hold |
1,475
| – | – | 0.03% | 169 |
|
|
2018
Q1 | $130K | Hold |
1,475
| – | – | 0.03% | 176 |
|
|
2017
Q4 | $125K | Buy |
1,475
+700
| +90% | +$58.6K | 0.03% | 172 |
|
|
2017
Q3 | $67K | Hold |
775
| – | – | 0.02% | 192 |
|
|
2017
Q2 | $60K | Buy |
775
+350
| +82% | +$24.8K | 0.01% | 206 |
|
|
2017
Q1 | $30K | Hold |
425
| – | – | 0.01% | 240 |
|
|
2016
Q4 | $25K | Buy |
+425
| New | +$26.2K | 0.01% | 249 |
|
Other funds holding XBI
Arrow Financial's XBI Position: Q1 2026 in Review
Arrow Financial held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 1,696 shares worth $217K. The position accounts for 0.02% of the portfolio, ranked #154.
Arrow Financial first reported a position in XBI in Q4 2016 and has held it in 34 quarters since. The position peaked at $217K in Q4 2020. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Arrow Financial held 1,696 shares of State Street SPDR S&P Biotech ETF worth $217K as of Q1 2026.
- Arrow Financial left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
- State Street SPDR S&P Biotech ETF made up 0.02% of Arrow Financial's portfolio in Q1 2026, its #154 holding.
- Arrow Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 34 quarters since.
- Arrow Financial's State Street SPDR S&P Biotech ETF position peaked at $217K in Q4 2020.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Arrow Financial's 13F filing for Q1 2026, filed 11 May 2026.